SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.

Drexel, H; Rosano, GMC; Lewis, BS; Huber, K; Vonbank, A; Dopheide, JF; Mader, A; Niessner, A; Savarese, G; Wassmann, S; et al. Drexel, H; Rosano, GMC; Lewis, BS; Huber, K; Vonbank, A; Dopheide, JF; Mader, A; Niessner, A; Savarese, G; Wassmann, S; Agewall, S (2020) The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. Eur Heart J Cardiovasc Pharmacother, 6 (2). pp. 97-103. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvz029
SGUL Authors: Rosano, Giuseppe Massimo Claudio

[img]
Preview
 PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (461kB) | Preview

Abstract

Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.

Item Type: Article
Additional Information: This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal Cardiovascular Pharmacotherapy following peer review. The version of record Heinz Drexel, Giuseppe M C Rosano, Basil S Lewis, Kurt Huber, Alexander Vonbank, Jörn F Dopheide, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Sven Wassmann, Stefan Agewall, The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 2, March 2020, Pages 97–103 is available online at: https://doi.org/10.1093/ehjcvp/pvz029
Keywords: Cardiovascular disease, Cardiovascular pharmacotherapy, Diabetes, Endpoints, Randomized clinical trial, Biomarkers, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Dyslipidemias, Endpoint Determination, Humans, Hypoglycemic Agents, Hypolipidemic Agents, Lipids, Randomized Controlled Trials as Topic, Research Design, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Humans, Cardiovascular Diseases, Diabetes Mellitus, Blood Glucose, Lipids, Hypoglycemic Agents, Treatment Outcome, Endpoint Determination, Risk Assessment, Risk Factors, Research Design, Time Factors, Dyslipidemias, Randomized Controlled Trials as Topic, Hypolipidemic Agents, Biomarkers
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J Cardiovasc Pharmacother
ISSN: 2055-6845
Language: eng
Dates:
DateEvent
1 April 2020Published
29 August 2019Published Online
10 July 2019Accepted
Publisher License: Publisher's own licence
PubMed ID: 31298686
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112953
Publisher's version: https://doi.org/10.1093/ehjcvp/pvz029

Statistics

Item downloaded times since 16 Feb 2021.

Actions (login required)

Edit Item Edit Item